Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Drones Spotted Near Zelenskiy’s Flight Path in Ireland Trigger Security Alert 
China’s Expanding Maritime Military Presence Alarms Taiwan and Japan 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Israel Receives Body of Deceased Hostage as Rafah Crossing Reopening Hinges on Final Returns 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Australia Progresses AUKUS Review as U.S. Affirms Strong Support 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
California Launches Portal for Reporting Alleged Misconduct by Federal Immigration Agents 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
New Orleans Immigration Crackdown Sparks Fear as Federal Arrests Intensify 
Trump Administration Halts Immigration, Green Card, and Citizenship Processing for 19 Countries 
Pfizer and U.S. President Donald Trump announced a landmark agreement on Tuesday, under which the pharmaceutical giant will lower prescription drug prices in the Medicaid program to levels comparable to other developed nations. In exchange, Pfizer secured tariff relief on its products. The deal positions Pfizer as the first drugmaker to comply with Trump’s push to align U.S. drug prices with global standards.
Under the agreement, Pfizer committed to applying most-favored-nation pricing on all new drugs launched in the U.S. from 2026. Trump also introduced TrumpRx, a White House-backed direct-to-consumer drug platform set to launch the same year, allowing Americans to access discounted medications directly. This move follows Trump’s earlier threats to impose a 100% tariff on branded pharmaceutical imports unless manufacturers boosted U.S. production.
Pfizer will invest $70 billion in domestic research, development, and manufacturing, securing a three-year grace period from the planned tariffs. CEO Albert Bourla confirmed the company would relocate more production to the U.S., where it currently operates nine manufacturing facilities. The deal covers a range of therapies, including Xeljanz, Zavzpret, Eucrisa, and Duavee, with discounts averaging 50% and in some cases reaching up to 85%.
The announcement boosted investor confidence, sending Pfizer shares up more than 6% and lifting other drugmakers like Eli Lilly, Merck, and Amgen. Analysts noted that limiting concessions to Medicaid minimized the industry’s financial impact, since Medicaid drug spending—around $80 billion annually—is smaller than Medicare’s $216 billion.
Industry experts believe this agreement may pressure rivals such as AstraZeneca and Eli Lilly, who have already pledged U.S. manufacturing expansion, to follow suit. While patients in Medicaid stand to benefit, health economists stress that the broader impact would be far greater if similar price cuts extended to Medicare.
By securing tariff relief while offering targeted price cuts, Pfizer and Trump’s administration have crafted a deal that may reshape U.S. drug pricing strategies ahead of TrumpRx’s 2026 launch.
